These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31836854)

  • 1. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
    Hu G; Phillips JL; Dasari S; Jacobs HK; Luchtel RA; Oishi N; Hundal T; Ahmed NH; Satou A; Epstein AL; Bennani NN; Nowakowski GS; Murray JA; Feldman AL
    Leukemia; 2020 May; 34(5):1467-1471. PubMed ID: 31836854
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent
    Sharma A; Oishi N; Boddicker RL; Hu G; Benson HK; Ketterling RP; Greipp PT; Knutson DL; Kloft-Nelson SM; He R; Eckloff BW; Jen J; Nair AA; Davila JI; Dasari S; Lazaridis KN; Bennani NN; Wu TT; Nowakowski GS; Murray JA; Feldman AL
    Blood; 2018 May; 131(20):2262-2266. PubMed ID: 29592893
    [No Abstract]   [Full Text] [Related]  

  • 3. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts.
    Leiting JL; Hernandez MC; Yang L; Bergquist JR; Ivanics T; Graham RP; Truty MJ
    Sci Rep; 2019 Apr; 9(1):5901. PubMed ID: 30976061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
    Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
    Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
    Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
    Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.
    Zhu S; Wang Z; Li Z; Peng H; Luo Y; Deng M; Li R; Dai C; Xu Y; Liu S; Zhang G
    Oncotarget; 2015 Apr; 6(12):10460-72. PubMed ID: 25865044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
    Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
    Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
    Jin J; Guo Q; Xie J; Jin D; Zhu Y
    Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells regulate the proliferation of T cells via the growth-related oncogene/CXC chemokine receptor, CXCR2.
    Lee YS; Won KJ; Park SW; Lee HW; Kim B; Kim JH; Kim DK
    Cell Immunol; 2012 Sep; 279(1):1-11. PubMed ID: 23023221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
    Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
    Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
    Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
    J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2.
    Huang H; Niu J; Wang F; Hu L; Yu Q
    Invest New Drugs; 2019 Jun; 37(3):452-460. PubMed ID: 30073465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
    Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
    Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.
    Du W; Hong J; Wang YC; Zhang YJ; Wang P; Su WY; Lin YW; Lu R; Zou WP; Xiong H; Fang JY
    J Cell Mol Med; 2012 Aug; 16(8):1878-88. PubMed ID: 22050790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
    Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
    Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.
    Borriello L; Nakata R; Sheard MA; Fernandez GE; Sposto R; Malvar J; Blavier L; Shimada H; Asgharzadeh S; Seeger RC; DeClerck YA
    Cancer Res; 2017 Sep; 77(18):5142-5157. PubMed ID: 28687621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.